children <12 years of age for CSU and the first report of successfultreatment of delayed pressure urticaria in children. Our small case series demonstrates that omalizumab is very effective in CSU patients with normal CD63 levels and that high CD63 expression level may indicate more persistent forms that may require more frequent injections or higher dosage. Larger studies are required to establish the role of CD63 expression as a potential marker …
Abstract
A letter to the editor is presented in response to the article" Physical urticaria," by JP Dice in the 2004 issue.